β-galactosidase (β-gal), a protein product of the bacterial LacZ gene, catalyzes the conversion of β-galactosides into monosaccharides. β-gal is a common marker gene used to assess transfection efficiency.
Capped with CleanCap® AG cap analog, no base modifications in the sequence
Cap 1 structure with >95% capping efficiency for superior in vivo activity compared to Cap-0 mRNAs
Manufactured with TriLink’s proprietary CleanScript® method to lower dsRNA for improved performance
Ready to use in downstream mRNA applications and formulations
Grade: RUO
This mRNA is capped using CleanCap® Reagent AG, TriLink's co-transcriptional capping technology, which results in the naturally occurring Cap-1 structure with >95% capping efficiency. It is manufactured using TriLink’s CleanScript® method, polyadenylated, and optimised for mammalian systems. It mimics a fully processed mature mRNA.
CleanCap Reagent AG produces a base-modified Cap-1 mRNA, which shows superior in vivo activity compared to Cap-0 mRNA produced by legacy capping methods such as mCap or anti-reverse cap analog (ARCA).
CleanScript method is TriLink’s proprietary in vitro transcription process that is optimised to minimise dsRNA formation and increase mRNA activity in vivo.